Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearmind Medicine Inc. (CMND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Clearmind submits current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage psychedelic pharmaceutical biotech company listed on Nasdaq and the Frankfurt Stock Exchange.
Through these filings, investors can review press releases that are formally incorporated by reference into Clearmind’s registration statements on Form F-3 and Form S-8. Recent Form 6-K reports have attached announcements about the FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, including positive top-line results from the first cohort, Data and Safety Monitoring Board approval to continue the trial, and expansion of the multinational clinical-site network. Other 6-K filings describe capital-raising transactions such as registered direct offerings of common shares and pre-funded warrants, with stated uses of proceeds for operating expenses, research and development, clinical and pre-clinical testing, working capital, and general corporate purposes.
Clearmind’s filings also document corporate actions relevant to CMND stock, including a 1-for-40 reverse share split and Nasdaq notifications regarding minimum bid price and stockholders’ equity requirements. These documents outline how the company has addressed exchange listing criteria and how related matters are monitored by Nasdaq. In addition, the filings identify Clearmind’s principal executive offices in Vancouver, British Columbia, and provide details on its intellectual property-focused business model and clinical-stage status.
On Stock Titan, Clearmind’s SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the context and key points of lengthy reports, making it easier to locate information on clinical trial disclosures, financing terms, and listing compliance without reading every page in detail. Users can also review historical filings to understand how Clearmind’s development programs, capital structure, and regulatory communications have evolved over time.
Clearmind Medicine announced a $10.0 million securities purchase agreement intended to explore strategic opportunities. The filing provides the transaction title but no additional terms, counterparties, or timing. The report is signed by CEO Adi Zuloff-Shani, confirming the company disclosed the financing arrangement publicly. With limited detail in this report, the primary fact is the existence of the $10 million agreement to support potential strategic initiatives.
Clearmind Medicine, Inc. submitted a Form 6-K that attaches a Form of Convertible Promissory Note and a Form of Securities Purchase Agreement dated
Clearmind Medicine Inc. submitted a Form 6-K to inform investors that, on September 11, 2025, it filed in Canada its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and nine months ended July 31, 2025. These documents were filed with the Canadian Securities Administration and the securities commissions in Ontario, British Columbia and Alberta.
The Form 6-K also states that this report is incorporated by reference into Clearmind’s existing U.S. registration statements on Form F-3 and Form S-8, meaning those offerings now formally include the latest Canadian interim financial statements and MD&A.